Virtual Conference

The 11th Asia-Pacific Primary Liver Cancer Expert Meeting

PROGRAM AT A GLANCE

Friday, August 13, 2021

ROOM 1

11:00
Opening (11:50-12:00)

12:00
Session 1
Risk Factors, Surveillance, and Prevention
(12:00-13:00)

13:00
Session 2
Diagnosis and Staging for HCC and CC
(13:10-14:10)

14:00
Session 3
Liver-Directed Therapy
(14:20-15:35)

15:00
Session 4
System Treatment for HCC and CC
(15:50-16:50)

16:00
Closing Remarks (16:50-17:00)
APPLE Academy Satellite Symposium
(17:00-17:30)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50-12:00</td>
<td>Opening Remark</td>
<td>Jinsil Seong (President)</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Session 1. Risk Factors, Surveillance and Prevention</td>
<td>Namiki Izumi (Musashino Red Cross Hospital, Tokyo)</td>
</tr>
<tr>
<td>12:00-12:15</td>
<td>Risk Factors and Prevention (Primary, Secondary, Tertiary)</td>
<td>Junqi Niu (Jilin Univ., Jilin)</td>
</tr>
<tr>
<td>12:15-12:30</td>
<td>Biomarkers for HCC and CC</td>
<td>Kwang-Hyub Han (NECA, Seoul)</td>
</tr>
<tr>
<td>12:30-12:45</td>
<td>Current Recommendation for HCC Surveillance</td>
<td>Young-Suk Lim (Univ. of Ulsan, Seoul)</td>
</tr>
<tr>
<td>12:45-13:00</td>
<td>Discussion</td>
<td>Namiki Izumi (Musashino Red Cross Hospital, Tokyo)</td>
</tr>
<tr>
<td>13:00-13:10</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>13:10-14:10</td>
<td>Session 2. Diagnosis and Staging for HCC and CC</td>
<td>Hirohisa Yano (Kurume Univ., Kurume)</td>
</tr>
<tr>
<td>13:10-13:25</td>
<td>Pathological Diagnosis for HCC and CC: New WHO Classification</td>
<td>Irene Ng (The Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>13:25-13:40</td>
<td>Imaging for HCC and CC: Diagnosis and Response Evaluation</td>
<td>Choon Hua Thng (National Cancer Centre Singapore, Singapore)</td>
</tr>
<tr>
<td>13:55-14:10</td>
<td>Case Discussion</td>
<td></td>
</tr>
<tr>
<td>14:10-14:20</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>14:20-15:35</td>
<td>Session 3. Liver-Directed Therapy</td>
<td>Pierce Chow (National Cancer Centre Singapore, Singapore)</td>
</tr>
<tr>
<td>14:20-14:35</td>
<td>Surgical Resection for HCC</td>
<td>Kyung-Suk Suh (Seoul National Univ., Seoul)</td>
</tr>
<tr>
<td>14:35-14:50</td>
<td>Liver Transplantation: Selection Criteria and Outcomes</td>
<td>Albert Chan (The Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>14:50-15:05</td>
<td>Transarterial Chemoembolization (TACE)</td>
<td>Jin Wook Chung (Seoul National Univ., Seoul)</td>
</tr>
<tr>
<td>15:05-15:20</td>
<td>Local Therapy Radiotherapy for HCC</td>
<td>Jason Chia-Hsien Cheng (National Taiwan Univ., Taipei)</td>
</tr>
<tr>
<td>15:20-15:35</td>
<td>Case Discussion</td>
<td></td>
</tr>
<tr>
<td>15:35-15:50</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>15:50-16:50</td>
<td>Session 4. Systemic Treatment for HCC and CC</td>
<td>Chiu Hsu (National Taiwan Univ., Taipei)</td>
</tr>
<tr>
<td>15:50-16:05</td>
<td>Systemic Therapy for HCC</td>
<td>Han Chong Toh (National Cancer Centre Singapore, Singapore)</td>
</tr>
<tr>
<td>16:05-16:20</td>
<td>Systemic Therapy for Cholangiocarcinoma</td>
<td>Stephen Lam Chan (The Chinese Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>16:20-16:35</td>
<td>Clinical Trial Design and Analysis: Lessons from Trials of Targeted Therapy and Immunotherapy for HCC</td>
<td>Masafumi Ikeda (National Cancer Center Hospital East, Tokyo)</td>
</tr>
<tr>
<td>16:35-16:50</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:50-17:00</td>
<td>Closing Remarks</td>
<td>Irene Ng and Chiu Hsu (Education Chairs)</td>
</tr>
<tr>
<td>17:00-17:30</td>
<td>APPLE Academy Satellite Symposium</td>
<td></td>
</tr>
</tbody>
</table>

APPLE ACADEMY 2021

This program is expected to become a stepping stone for our next generation of doctors and non-expert doctors who are interested in liver cancer.
<table>
<thead>
<tr>
<th>Time</th>
<th>ROOM 1</th>
<th>ROOM 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td><strong>Session 1</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epidemiology and Surveillance of HCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(08:30-10:00)</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td>Opening Remark (10:10-10:20)</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td><strong>Session 2</strong></td>
<td><strong>Session 3</strong></td>
</tr>
<tr>
<td></td>
<td>Surgery and Liver Transplantation of HCC</td>
<td>Antiviral Therapy and HCC</td>
</tr>
<tr>
<td></td>
<td>(11:00-12:30)</td>
<td>(11:00-12:30)</td>
</tr>
<tr>
<td>13:30</td>
<td><strong>Satellite Symposium - Eisai</strong></td>
<td><strong>Satellite Symposium - J&amp;J and Hengrui</strong></td>
</tr>
<tr>
<td></td>
<td>(12:30-13:10)</td>
<td>(12:30-13:10)</td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td><strong>Session 4</strong></td>
<td><strong>Session 5</strong></td>
</tr>
<tr>
<td></td>
<td>Locoregional Therapy for HCC: New Roles in Immunotherapy Era</td>
<td>Molecular Pathogenesis and Pathology of HCC</td>
</tr>
<tr>
<td></td>
<td>(13:10-14:40)</td>
<td>(13:10-14:30)</td>
</tr>
<tr>
<td>15:55</td>
<td>State-of-the-Art Lecture 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(15:55-16:35)</td>
<td></td>
</tr>
<tr>
<td>16:40</td>
<td><strong>Session 6</strong></td>
<td><strong>Session 7</strong></td>
</tr>
<tr>
<td></td>
<td>Systemic Therapy for Earlier-Stages of HCC</td>
<td>Imaging Diagnosis of HCC</td>
</tr>
<tr>
<td></td>
<td>(14:50-15:45)</td>
<td>(14:50-16:10)</td>
</tr>
<tr>
<td>17:20</td>
<td><strong>APPLE General Assembly</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(16:40-17:20)</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td><strong>Satellite Symposium - Roche</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(17:20-18:00)</td>
<td></td>
</tr>
</tbody>
</table>

*GMT+09:00 (Seoul, Tokyo)*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Presidential Lecture</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>Session 1. Epidemiology and Surveillance of HCC</td>
<td>Takuji Torimura (Kurume Univ., Kurume), Do Young Kim (Yonsei Univ., Seoul)</td>
</tr>
<tr>
<td>08:30-08:50</td>
<td>Global Epidemiology and Risk Factors of HCC</td>
<td>Man-Fung Yuen (The Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>08:50-09:10</td>
<td>HCC in Patients with NASH: Epidemiology, Risk Factors, and Surveillance</td>
<td>Ryosuke Tateishi (The Univ. of Tokyo, Tokyo)</td>
</tr>
<tr>
<td>09:10-09:30</td>
<td>Cost-Effectiveness of HCC Surveillance</td>
<td>Amit Singal (UT Southwestern Medical Center, Texas)</td>
</tr>
<tr>
<td>09:30-09:50</td>
<td>Outcome of National HCC Surveillance Program in Korea</td>
<td>Do Young Kim (Yonsei Univ., Seoul)</td>
</tr>
<tr>
<td>09:50-10:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:00-10:10</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:10-10:20</td>
<td>Opening Remark</td>
<td>Jinsil Seong (President, APPLE)</td>
</tr>
<tr>
<td>10:20-10:50</td>
<td>Presidential Lecture</td>
<td>Ann-Lii Cheng (National Taiwan Univ., Taipei)</td>
</tr>
<tr>
<td>10:50-11:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00-12:30</td>
<td>Session 2. Surgery and Liver Transplantation of HCC</td>
<td>Etsuro Hatano (Kyoto Univ., Hyogo), Linda Wong (Univ. of Hawaii Cancer Center, Hawaii)</td>
</tr>
<tr>
<td>11:00-11:20</td>
<td>The Updates and Future of Liver Surgery in the New Eras of TKI Drug and Immunotherapy</td>
<td>Kiyoshi Hasegawa (The Univ. of Tokyo, Tokyo)</td>
</tr>
<tr>
<td>11:20-11:40</td>
<td>Surgical Management beyond the BCLC Guideline</td>
<td>Tan To Cheung (The Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>11:40-12:00</td>
<td>Minimally Invasive LDLT</td>
<td>Kyung-Suk Suh (Seoul National Univ., Seoul)</td>
</tr>
<tr>
<td>12:00-12:20</td>
<td>Precision Therapies in Liver Transplantation for Cancer Recurrence: Biology, Genomics and Immunology</td>
<td>Jian Zhou (Fudan Univ., Shanghai)</td>
</tr>
<tr>
<td>12:20-12:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:30-13:10</td>
<td>Satellite Symposium - Eisai</td>
<td></td>
</tr>
<tr>
<td>13:10-14:40</td>
<td>Session 4. Locoregional Therapy for HCC: New Roles in Immunotherapy Era</td>
<td>Namiki Izumi (Musashino Red Cross Hospital, Tokyo), Guohong Han (Fourth Military Medical Univ., Xi’an)</td>
</tr>
<tr>
<td>13:30-13:50</td>
<td>Future Role of Locoregional Therapy for HCC: Hepatologist’s Perspective</td>
<td>Joong-Won Park (National Cancer Center Korea, Goyang)</td>
</tr>
<tr>
<td>13:50-14:10</td>
<td>Local Radiotherapy as an Immunomodulator in HCC</td>
<td>Jason Chia-Hsien Cheng (National Taiwan Univ., Taipei)</td>
</tr>
<tr>
<td>14:10-14:30</td>
<td>Abscopal Effect of Radiotherapy for HCC</td>
<td>Hee Chul Park (Sungkyunkwan Univ., Seoul)</td>
</tr>
<tr>
<td>14:30-14:40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:40-14:50</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>14:50-15:10</td>
<td>Role of Systemic Therapy in Early HCC Patients: Hepatologist Perspectives</td>
<td>15:55-16:35</td>
</tr>
<tr>
<td>14:50-15:10</td>
<td>Masatoshi Kudo (Kindai Univ., Osaka)</td>
<td></td>
</tr>
<tr>
<td>15:10-15:30</td>
<td>Systemic Therapy for Earlier-Stages of HCC: IR Perspectives</td>
<td>15:30-15:45</td>
</tr>
<tr>
<td>15:30-15:45</td>
<td>Jin Wook Chung (Seoul National Univ., Seoul)</td>
<td></td>
</tr>
<tr>
<td>15:45-15:55</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:35-16:40</td>
<td>Break</td>
<td>16:30-16:40</td>
</tr>
<tr>
<td>16:40-17:20</td>
<td>APPLE General Assembly</td>
<td>16:40-17:20</td>
</tr>
<tr>
<td>17:20-18:00</td>
<td>Satellite Symposium - Roche</td>
<td>17:20-18:00</td>
</tr>
</tbody>
</table>

**GMT+09:00 (Seoul, Tokyo) SATURDAY, AUGUST 14, 2021**

**Room 1**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session 3. Antiviral Therapy and HCC</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:20</td>
<td>Risk Models for HCC Development under Antiviral Therapy in CHB</td>
<td>Jia-Horng Kao (National Taiwan Univ., Taipei)</td>
</tr>
<tr>
<td>11:20-11:40</td>
<td>Comparison of Tenofovir vs Entecavir on Reducing Incidence of HCC in CHB</td>
<td>Jidong Jia (Capital Medical Univ., Beijing)</td>
</tr>
<tr>
<td>11:40-12:00</td>
<td>Antiviral Therapy in Immune-Tolerant CHB: Pros</td>
<td>Young-Suk Lim (Univ. of Ulsan, Seoul)</td>
</tr>
<tr>
<td>12:00-12:20</td>
<td>Antiviral Therapy in Immune-Tolerant CHB: Cons</td>
<td>Grace L. H. Wong (The Chinese Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>12:20-12:30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 5. Molecular Pathogenesis and Pathology of HCC</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:10-13:30</td>
<td>Intratumoural Immune Heterogeneity as a Hallmark of Tumour Evolution in HCC</td>
<td>Valerie Chew (Duke-NUS Medical School, Singapore)</td>
</tr>
<tr>
<td>13:30-13:50</td>
<td>Pathological and Molecular Features Related to Cancer Stemness of HCC</td>
<td>Young Nyun Park (Yonsei Univ., Seoul)</td>
</tr>
<tr>
<td>13:50-14:10</td>
<td>HCC Genomics Using Single Cell Analysis</td>
<td>Irene Ng (The Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>14:10-14:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:30-14:50</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 7. Imaging Diagnosis of HCC</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:50-15:10</td>
<td>LI-RADS: Pitfalls and Problems or How to Use LR-M and Ancillary Features</td>
<td>Victoria Chernyak (Albert Einstein College of Medicine, New York)</td>
</tr>
<tr>
<td>15:10-15:25</td>
<td>MR Imaging Phenotype of HCC and Histologic Correlation</td>
<td>Jin-Young Choi (Yonsei Univ., Seoul)</td>
</tr>
<tr>
<td>15:25-15:45</td>
<td>Application of Radiomics for Primary Liver Cancer</td>
<td>Seung Soo Lee (Univ. of Ulsan, Seoul)</td>
</tr>
<tr>
<td>15:45-16:00</td>
<td>AI for the Prediction, Diagnosis, and Treatment of HCC</td>
<td>Jeong-Hoon Lee (Seoul National Univ., Seoul)</td>
</tr>
<tr>
<td>16:00-16:10</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Room 1</td>
<td>Room 2</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------</td>
</tr>
<tr>
<td>08:00</td>
<td>Satellite Symposium - Eisai (08:00-09:00)</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td><strong>Session 8</strong>&lt;br&gt; Multidisciplinary Approach in Vascular Invasive HCC &lt;br&gt; (09:00-10:30)</td>
<td><strong>Session 9</strong>&lt;br&gt; Cholangiocarcinoma (09:00-10:10)</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>Session 10</strong>&lt;br&gt; Systemic Therapy for Advanced HCC &lt;br&gt; (10:40-12:10)</td>
<td><strong>Session 11</strong>&lt;br&gt; Abstract Oral Presentation &lt;br&gt; (10:40-12:00)</td>
</tr>
<tr>
<td>12:00</td>
<td>State-of-the-Art Lecture 2 &lt;br&gt; (12:10-12:50)</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Wrap-up and Closing (12:50-13:00)</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Presenters</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>08:00-09:00</td>
<td>Satellite Symposium - Eisai</td>
<td></td>
</tr>
<tr>
<td>09:00-10:30</td>
<td>Session 8. Multidisciplinary Approach in</td>
<td>Kwang-Hyub Han (NECA, Seoul),</td>
</tr>
<tr>
<td></td>
<td>Vascular Invasive HCC</td>
<td>Norihiro Kokudo (National Center for Global</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Health and Medicine, Tokyo)</td>
</tr>
<tr>
<td>09:00-09:20</td>
<td>Hepatologist Perspectives</td>
<td>Jeong Won Jang (The Catholic Univ. of Korea,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seoul)</td>
</tr>
<tr>
<td>09:20-09:40</td>
<td>Surgeon Perspectives</td>
<td>Norihiro Kokudo (National Center for Global</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Health and Medicine, Tokyo)</td>
</tr>
<tr>
<td>09:40-10:00</td>
<td>Interventional Oncologist Perspectives</td>
<td>Chien-An Liu (Taipei Veterans General Hospital,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Taipei)</td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>Radiation Oncologist Perspectives</td>
<td>Laura Dawson (Univ. of Toronto, Toronto)</td>
</tr>
<tr>
<td>10:20-10:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:30-10:40</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:40-12:10</td>
<td>Session 10. Systemic Therapy for Advanced HCC</td>
<td>Sheng-Long Ye (Fudan Univ., Shanghai),</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Masatoshi Kudo (Kindai Univ., Osaka)</td>
</tr>
<tr>
<td>10:40-11:00</td>
<td>Systemic Therapy for HCC: What Will Be the</td>
<td>Ann-Lii Cheng (National Taiwan Univ., Taipei)</td>
</tr>
<tr>
<td></td>
<td>Next</td>
<td></td>
</tr>
<tr>
<td>11:00-11:20</td>
<td>Tumor Immune Microenvironment-Based</td>
<td>Ghassan Abou-Alfa (Memorial Sloan-Kettering</td>
</tr>
<tr>
<td></td>
<td>Immunotherapy</td>
<td>Cancer Center, New York)</td>
</tr>
<tr>
<td>11:20-11:40</td>
<td>Combination Immunotherapy with Anti-VEGF</td>
<td>Richard Finn (Univ. of California LA, LA)</td>
</tr>
<tr>
<td></td>
<td>Multikinase Inhibitor</td>
<td></td>
</tr>
<tr>
<td>11:40-12:00</td>
<td>Combination Immunotherapy with Anti-CTLA-4</td>
<td>Thomas Yau (The Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td></td>
<td>Antibody</td>
<td></td>
</tr>
<tr>
<td>12:00-12:10</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:10-12:50</td>
<td>State-of-the-Art Lecture 2</td>
<td>Jinsil Seong (Yonsei Univ., Seoul)</td>
</tr>
<tr>
<td></td>
<td>Radiation and Checkpoint Blockade Immunotherapy</td>
<td>Andrew Sharabi (The Univ. California San Diego,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>San Diego)</td>
</tr>
<tr>
<td>12:50-13:00</td>
<td>Wrap-up and Closing</td>
<td>Chih-Hung Hsu [Secretary General, APPLE]</td>
</tr>
<tr>
<td>Time</td>
<td>Session 9. Cholangiocarcinoma</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>09:00</td>
<td>Update of Combined Hepatocellular-Cholangiocarcinoma</td>
<td>Matthew Yeh (Univ. of Washington, Seattle)</td>
</tr>
<tr>
<td>09:20</td>
<td>Progress of Chemotherapy and Targeted Therapy in Cholangiocarcinoma</td>
<td>Masafumi Ikeda (National Cancer Center Hospital East, Tokyo)</td>
</tr>
<tr>
<td>09:40</td>
<td>Immunotherapy for Cholangiocarcinoma: Hope or Hype?</td>
<td>Andrew Zhu (Jiahui International Cancer Center, Shanghai)</td>
</tr>
<tr>
<td>10:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 11. Abstract Oral Presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40</td>
<td>Comparisons of Three Serum Biomarkers Alone and in Combination for Detection of HCC in Patients with Nonalcoholic Fatty Liver Disease: A Multicenter Case-Control Study</td>
<td>Tian Yang (Second Military Medical Univ., Shanghai)</td>
</tr>
<tr>
<td>10:50</td>
<td>Single-Cell RNA Sequencing Shows the Immunosuppressive Landscape and Tumor Heterogeneity of HBV-Associated HCC</td>
<td>Daniel Wai-Hung Ho (The Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>11:00</td>
<td>Liver Transplantation vs Partial Hepatectomy for Stage T2 Multifocal HCC: A Propensity-Score Matched Analysis</td>
<td>Kliment Bozhilov (Queen’s Medical Center, Hawaii)</td>
</tr>
<tr>
<td>11:10</td>
<td>Combined Stereotactic Body Radiotherapy (SBRT) and Immunotherapy vs SBRT in Locally Advanced HCC: Propensity Score Matching Analysis</td>
<td>Chiang Chi Leung (The Univ. of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>11:30</td>
<td>Transcatheter Arterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable HCC [TACTICS-L] in Japan: Interim Analysis</td>
<td>Issei Saeki (Yamaguchi Univ., Yamaguchi)</td>
</tr>
<tr>
<td>11:40</td>
<td>IMBrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib by Baseline Varices Status in Patients with HCC</td>
<td>Philippe Merte (Hospital La Croix-Rousse, Lyon)</td>
</tr>
<tr>
<td>11:50</td>
<td>Nivolumab Plus Ipilimumab [N+I] as Neoadjuvant Therapy for Potentially Resectable HCC</td>
<td>Yung-Yeh Su (National Health Research Institute, Taiwan)</td>
</tr>
</tbody>
</table>
Comparisons of Three Serum Biomarkers Alone and in Combination for Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Multicenter Case-Control Study
- Tian Yang (Second Military Medical University, China)

Single-Cell RNA Sequencing Shows the Immunosuppressive Landscape and Tumor Heterogeneity of HBV-Associated Hepatocellular Carcinoma
- Daniel Wai-Hung Ho (The University of Hong Kong, Hong Kong)

Liver Transplantation versus Partial Hepatectomy for Stage T2 Multifocal Hepatocellular Carcinoma: A Propensity-Score Matched Analysis
- Kliment Bozhilov (Queen’s Medical Center, USA)

Combined Stereotactic Body Radiotherapy (SBRT) and Immunotherapy versus SBRT in Locally Advanced Hepatocellular Carcinoma: Propensity Score Matching Analysis
- CHIANG Chi Leung (The University of Hong Kong, Hong Kong)

Stereotactic Ablative Body Radiotherapy for Oligometastatic Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study [KROG 20-04]
- Tae Hyung Kim (Eulji University, South Korea)

Transcatheter Arterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma (TACTICS-L) in Japan: Interim Analysis
- Issie Saeki (Yamaguchi University, Japan)

IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib by Baseline Varices Status in Patients with Hepatocellular Carcinoma (HCC)
- Philippe Merle (University Hospital La Croix-Rousse, France)

Nivolumab Plus Ipilimumab (N+I) as Neoadjuvant Therapy for Potentially Resectable Hepatocellular Carcinoma (HCC)
- Yung-Yeh Su (National Health Research Institute, Taiwan)

Automated Segmentation on Multiphasic Computed Tomography Simulation in Radiotherapy to Liver Cancer Using Three-Dimensional Deep Neural Networks
- Shao-Lun Lu (National Taiwan University, Taiwan)

YAP/TAZ Expression in Hepatocellular Carcinoma (HCC) and Effects of YAP/TAZ Inhibition on HCC
- Sojung Han (Eulji University, South Korea)

Orchestrating the Spatial and Single-Cell Immune Landscape of Colorectal Cancer Liver Metastasis
- Yingcheng Wu (Fudan University, China)
**Diagnosis and Liver Imaging**

**FY-06**

Early Complete Tumor Response as a Survival Predictor In Hepatocellular Carcinoma Patients Receiving Stereotactic Body Radiation Therapy  
Qi-Giao Wu (Fudan University, China)

**Epidemiology and Surveillance**

**FY-07**

Portal Vein Thrombosis in Pakistani Population with Hepatocellular Carcinoma – Prevalence and Risk Factors  
Tayyab Siddiqui (Aga Khan University, Pakistan)

**Molecular Pathogenesis and Pathology**

**FY-08**

Dysregulation of RalA Signaling through Dual Regulatory Mechanisms Exerts Its Oncogenic Functions in Hepatocellular Carcinoma  
Lu Tian (The University of Hong Kong, Hong Kong)

**FY-09**

Cancer Testis Antigen PAGE4 on Tumor-associated Macrophages Promotes Invasion and Metastasis of CTNNB1-mutated Hepatocellular Carcinoma via CD36  
Juan Zhang (Fudan University, China)

**FY-10**

Activation of the NLRP3 Inflammasome in Hepatitis C Virus-Related Hepatocellular Carcinoma: Relation to Oxidative Stress and Tumor Progression  
Hoda El Aggan (Alexandria University, Egypt)

**Staging and Prognosis**

**FY-11**

Pattern and Clinical Significance of Lymph Node Metastasis from Hepatocellular Carcinoma  
Byung Min Lee (Yonsei University, South Korea)

**FY-12**

A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma  
Shu-Yein Ho (Min-Sheng General Hospital, Taiwan)

**FY-13**

Identification of a Pyroptosis-Related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma  
Zheng Su Su (Fudan University, China)
### Treatment: Clinical Trials

**FV-14**  
Lenvatinib Plus Pembrolizumab for Patients with Previously Treated Biliary Tract Cancers in the Multicohort Phase 2 LEAP-005 Study  
*Hyun Cheol Chung [Yonsei University, South Korea]*

**FV-15**  
Atezolizumab Plus Bevacizumab (A+B) for Patients with Unresectable Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection with High Viral Load  
*San-Chi Chen [Taipei Veterans General Hospital, Taiwan]*

### Treatment: Novel Target or Experimental Therapy

**FV-16**  
Nano-delivery of Simvastatin to Liver Sinusoidal Endothelial Cells Inhibits Hepatocellular Carcinoma via Tumor Microenvironment Remodeling  
*Zhuo Yu [Shanghai University of Traditional Chinese Medicine, China]*

**FV-17**  
Bufalin Stimulates Immune Response in Hepatocellular Carcinoma by Reprogramming Tumor-Infiltrating Macrophage toward M1 Phenotype  
*Hai Feng [Shanghai University of Traditional Chinese Medicine, China]*

### Treatment: Surgical Resection and Transplantation

**FV-18**  
Outcomes of Living Donor Liver Transplantation in Patients with a History of Ruptured Hepatocellular Carcinoma  
*Suk Kyun Hong [Seoul National University, South Korea]*

**FV-19**  
Surgical Outcomes of Fibrolamellar Hepatocellular Carcinoma Patients: SEER Database Study  
*Tomoki Sempokuya [University of Nebraska Medical Center, USA]*

**FV-20**  
Comparison of Clinical Outcome between Minimally Invasive and Open Hepatectomy at High Difficulty Score for Hepatocellular Carcinoma  
*Kelvin K.C. Ng [The Chinese University of Hong Kong, Hong Kong]*

**FV-21**  
Long-term Survival of Elderly Patients Undergoing Curative Liver Resection for Early-Stage Hepatocellular Carcinoma: An International Multicenter Competing Risk Analysis  
*Tian Yang [Second Military Medical University, China]*

### Treatment: Systemic or Targeted Therapy

**FV-22**  
Early Serum Tumor Marker Responses Predict the Efficacy of Lenvatinib Plus an Anti-PD-1 Antibody in Unresectable Hepatocellular Carcinoma  
*Xiao-Dong Zhu [Fudan University, China]*

**FV-23**  
Prognosis and Second-Line Treatment Outcome of Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab and Bevacizumab Treatment  
*Ching-Tso Chen [National Taiwan University, Taiwan]*

**FV-24**  
Effects of Combination Therapy using Lenvatinib and an Anti-PD-1 Antibody on Liver Function in Patients with Advanced Hepatocellular Carcinoma  
*Ying-Hao Shen [Fudan University, China]*
### Treatment: Transarterial Approach/Percutaneous Ablative Therapy /Radiation Therapy

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>FV-25</td>
<td>Chemoprevention of Recurrent Hepatocellular Carcinoma after Liver Resection May Be Possible with Aspirin in Diabetic Patients</td>
<td>Larry Ray Hromalik (University of Hawaii, USA)</td>
</tr>
<tr>
<td>FV-26</td>
<td>Adjuvant Lenvatinib After Radical Resection in Patients with Hepatocellular Carcinoma (HCC): Preliminary Analysis of a Prospective, Multi-Center, Single-Arm Study</td>
<td>Hui-Chuan Sun (Fudan University, China)</td>
</tr>
<tr>
<td>FV-27</td>
<td>Lenvatinib (LEN) plus Anti-PD-1 Antibodies in Patients with Unresectable Hepatocellular Carcinoma (uHCC) Who Progressed on Front-Line LEN: Real-World Data from China</td>
<td>Yi Chen (Fudan University, China)</td>
</tr>
<tr>
<td>FV-28</td>
<td>Liver-Directed Concurrent Chemoradiotherapy Versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus</td>
<td>Jina Kim (Yonsei University, South Korea)</td>
</tr>
<tr>
<td>FV-29</td>
<td>Etiology-Dependent Tumor Control Probability Model after Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study</td>
<td>Nalee Kim (Sungkyunkwan University, South Korea)</td>
</tr>
<tr>
<td>FV-30</td>
<td>Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and Right Atrium Treated with Palliative Radiation Therapy and Lenvatinib</td>
<td>Adeodatus Vito Nicanor (Makati Medical Center, Philippines)</td>
</tr>
<tr>
<td>FV-31</td>
<td>Development and Validation of A Novel Online Calculator for Estimating Survival Benefit of Adjuvant Transcatheter Arterial Chemoembolization in Patients Undergoing Surgery for Hepatocellular Carcinoma</td>
<td>Tian Yang (Eastern Hepatobiliary Surgery Hospital, China)</td>
</tr>
<tr>
<td>FV-32</td>
<td>Development of a Prognostic Scoring System for Hepatocellular Carcinoma Patients with Main Portal Vein Tumor Thrombus Undergoing Conventional Transarterial Chemoembolization: An Analysis of 173 Patients</td>
<td>Jing-huan Li (Fudan University, China)</td>
</tr>
<tr>
<td>FV-33</td>
<td>Development of a Prognostic Score for Recommended TACE Candidates with Hepatocellular Carcinoma Spontaneous Rupture</td>
<td>Jixue Zou (Fudan University, China)</td>
</tr>
<tr>
<td>FV-34</td>
<td>Establishment of a Nomogram for Prognostic Prediction in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization</td>
<td>Zhongchen Li (Fudan University, China)</td>
</tr>
</tbody>
</table>

### Other Hepatobiliary Diseases

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>FV-35</td>
<td>Via mTOR Signaling Pathway LONP1 Protects Hepatocyte Oxidative Damage through Increase of Gluconeogenesis</td>
<td>Mu-Chen Wu (Beijing You-An Hospital, China)</td>
</tr>
</tbody>
</table>
## E-POSTER EXHIBITION

### Biomarkers

<table>
<thead>
<tr>
<th>PE-01</th>
<th>Sarcopenia and Myosteatosis Are Associated with Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Immunotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bang-Bin Chen (National Taiwan University, Taiwan)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE-02</th>
<th>An Immune-Related Gene Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Feng Zhang (Fudan University, China)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE-03</th>
<th>Matrix Stiffness Up-regulates the expression of SCD1 and Promotes the Invasion of Hepatocellular Carcinoma Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hua-Hua Liu (Fudan University, China)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE-04</th>
<th>Role of Interleukin-7 in the Development of and Recovery from Radiation-Induced Lymphopenia: A Post-Hoc Analysis of a Prospective Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hwa Kyung Byun (Yonsei University, South Korea)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE-05</th>
<th>Expression of USP46 and Its Prognostic Role in Hepatocellular Carcinoma: Analysis Based on the Data-Mining</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WU Yanfang (Fudan University, China)</td>
</tr>
</tbody>
</table>

### Cell Biology and Translational Research

<table>
<thead>
<tr>
<th>PE-06</th>
<th>Single-Cell Transcriptomic Analysis Reveals Two Molecularly and Clinically Distinct Subtypes of Intrahepatic Cholangiocarcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Guohe Song (Fudan University, China)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE-07</th>
<th>Significance of TERT Genetic Alterations and Telomere Length in Hepatocellular Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jin Seoub Kim (The Catholic University of Korea, South Korea)</td>
</tr>
</tbody>
</table>

### Cirrhosis and Related Complications

<table>
<thead>
<tr>
<th>PE-08</th>
<th>Comparison of the AIMS65 to Liver Severity Score in Predicting Mortality and Rebleeding in Liver Cirrhosis Patients with Acute Variceal Bleeding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Myeong Jun Song (The Catholic University of Korea, South Korea)</td>
</tr>
</tbody>
</table>

### Diagnosis and Liver Imaging

<table>
<thead>
<tr>
<th>PE-09</th>
<th>Imaging Findings of Liver MRI with Liver-Specific Contrast and the Risk of Hepatocellular Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jong-In Chang (Sungkyunkwan University, South Korea)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE-10</th>
<th>Category M of the Liver Imaging Reporting and Data System Version 2018 using MRI: A Systematic Review and Meta-Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sunyoung Lee (Yonsei University, South Korea)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE-11</th>
<th>Utility of Ancillary Magnetic Resonance Imaging Features in Liver Imaging and Reporting Data System Treatment Response Algorithm for Hepatocellular Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yeun-Yoon Kim (Yonsei University, South Korea)</td>
</tr>
<tr>
<td>PE-12</td>
<td>Lung and Lymph Node Metastases from Hepatocellular Carcinoma: Comparison of Pathological Aspects</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Ha Young Woo (National Cancer Center, South Korea)</td>
</tr>
<tr>
<td>PE-13</td>
<td>Nrf2 Imparts Ferroptosis Resistance in Hepatocellular Carcinoma Via ASPH/PI3K/Akt Axis</td>
</tr>
<tr>
<td></td>
<td>Jing Wu (Capital Medical University, China)</td>
</tr>
<tr>
<td>PE-14</td>
<td>YAP Inactivation in Estrogen Receptor Alpha-Positive Hepatocellular Carcinoma with Less Aggressive Behavior</td>
</tr>
<tr>
<td></td>
<td>Taek Chung (Yonsei University, South Korea)</td>
</tr>
<tr>
<td>PE-15</td>
<td>Fast Computational Viral Integration Detection in HBV-Associated Hepatocellular Carcinoma</td>
</tr>
<tr>
<td></td>
<td>Xueying Lyu (The University of Hong Kong, Hong Kong)</td>
</tr>
</tbody>
</table>

**Molecular Pathogenesis and Pathology**

**Staging and Prognosis**

<table>
<thead>
<tr>
<th>PE-16</th>
<th>Prognostic Nomogram of Recurrent Hepatocellular Carcinoma Treated with Radiofrequency Ablation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diyang Xie (Fudan University, Hong Kong)</td>
</tr>
<tr>
<td>PE-17</td>
<td>Prognostic Significance of TGR in Patients with Huge Hepatocellular Carcinoma undergoing Transcatheter Arterial Chemoembolization</td>
</tr>
<tr>
<td></td>
<td>Guobin Chen (Fudan University, China)</td>
</tr>
<tr>
<td>PE-18</td>
<td>The Overall Survival of Hepatocellular Carcinoma after Resection according to the Cause of Liver Disease</td>
</tr>
<tr>
<td></td>
<td>Hyun Woong Lee (Yonsei University, South Korea)</td>
</tr>
<tr>
<td>PE-19</td>
<td>The Predictive Value of Enhanced Liver Fibrosis (ELF) Score for the Patient with Hepatocellular Carcinoma after Liver Resection</td>
</tr>
<tr>
<td></td>
<td>Munseok Choi (Yonsei University, South Korea)</td>
</tr>
</tbody>
</table>

**Treatment: Novel Target or Experimental Therapy**

<table>
<thead>
<tr>
<th>PE-20</th>
<th>Mid-Line 1 Interacting Protein 1 (MID1IP1) Promotes Metastasis via AMPK-Mediated MMP9 Signalling in Hepatocellular Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Elley Yung-Tuen Chiu (The University of Hong Kong, Hong Kong)</td>
</tr>
</tbody>
</table>

**Treatment: Systemic or Targeted Therapy**

<table>
<thead>
<tr>
<th>PE-21</th>
<th>TACE Treatment in Combination with or without Sorafenib in HCC Patients with BCLC Stage B: A Systematic Review</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aldi Nanda Kurniawan (Pelita Harapan University, Indonesia)</td>
</tr>
<tr>
<td>PE-22</td>
<td>Modified ALBI Grade for Predicting Hepatocellular Carcinoma Prognosis among Who Treated with ICI plus TKI – A Real-World Practice</td>
</tr>
<tr>
<td></td>
<td>Hong Chen (Fudan University, China)</td>
</tr>
</tbody>
</table>
## E-POSTER EXHIBITION

### PE-23
Combination Therapy of Tyrosine Kinase Inhibitor and Immunotherapy for Patients with Unresectable Hepatocellular Carcinoma: Single Center Experience  

*Shou-Wu Lee (Taichung Veterans General Hospital, Taiwan)*

### PE-24
Efficacy of Radiofrequency Ablation vs Percutaneous Ethanol Injection in Hepatocellular Carcinoma Patients: A Systematic Review  

*Audrey Hadisurya (Pelita Harapan University, Indonesia)*

### PE-25
Successful Hepatocellular Carcinoma Downstaging with Preoperative Stereotactic Body Radiotherapy: Retrospective Evaluation of Pathologic Response  

*Gong Li (Beijing Tsinghua University, China)*

### PE-26
Efficacy and Safety of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Elderly Patients  

*Jinhong Jung (University of Ulsan, South Korea)*

### PE-27
Local Intervention for Skull Base Metastasis in Hepatocellular Carcinoma  

*Kangpyo Kim (Yonsei University, South Korea)*

### PE-28
Applying a Thoracoabdominal Aorta CTA-Based Nomogram Model to Identify Good Candidats for Transradial Approach Chemoembolization in Patients with Liver Cancer: A Pilot Study  

*Miao Li (Fudan University, China)*

### PE-29
Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis  

*Seo Hee Choi (Yonsei University, South Korea)*

### PE-30
A Comparative Study of Microwave and Radiofrequency Ablation Therapy for Hepatocellular Carcinoma  

*Soon Kyu Lee (The Catholic University of Korea, South Korea)*

### PE-31
Ultrasound Fusion Imaging (UFI) 101 for Liver Tumours  

*Sudharsan Madhavan (Singapore General Hospital, Singapore)*

### PE-32
Stereotactic Body Radiotherapy using Helical Tomotherapy for Hepatocellular Carcinoma as Treatment Stage Alternative Approach  

*Sun Hyun Bae (Soochunhyang University, South Korea)*

### PE-33
Radiofrequency Ablation versus Combined Transarterial Chemoembolization for Massive Recurrence of Early Unifocal Hepatocellular Carcinoma  

*Weike Chu (Tianjin Medical University, China)*

### Viral Hepatitis

### PE-34
A Nationwide Prospective Cohort Study on Chronic Hepatitis B in Korea: An Interim Analysis  

*Jae Seung Lee (Yonsei University, South Korea)*
### E-POSTER EXHIBITION

<table>
<thead>
<tr>
<th>PE-35</th>
<th>Comparison of the Occurrence of Hepatocellular Carcinoma in Patients of Chronic Hepatitis B Treated with Entecavir and Tenofovir</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tae Hyung Kim (Korea University, South Korea)</td>
</tr>
</tbody>
</table>

### Other Hepatobiliary Diseases

<table>
<thead>
<tr>
<th>PE-36</th>
<th>Role of Adjuvant Chemoradiotherapy in Perihilar Bile Duct Cancer: A Single Institutional Long-Term Follow up Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Choong-won Lee (Seoul National University, South Korea)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE-37</th>
<th>Phase 2 Multicohort Study of Lenvatinib Plus Pembrolizumab in Patients with Previously Treated Selected Solid Tumors: LEAP-005 Pancreatic Cancer Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hyun Cheol Chung (Yonsei University, South Korea)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE-38</th>
<th>Benefit of Adjuvant Radiotherapy for Gallbladder Cancer: A Comparability-Based Meta-Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Seo Hee Choi (Yonsei University, South Korea)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE-39</th>
<th>Gall Bladder Perforation In Cardiac Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Muhammad Zakria (Wapda Medical Complex, Pakistan)</td>
</tr>
</tbody>
</table>

### Miscellaneous

<table>
<thead>
<tr>
<th>PE-40</th>
<th>Hepatectomy for Liver Cancer under Influence of COVID-19 in a Regional Hospital in Hong Kong</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yue Sun Cheung (North District Hospital, Hong Kong)</td>
</tr>
</tbody>
</table>